The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors.
about
Selective gene silencing by viral delivery of short hairpin RNAErythroid-specific human factor IX delivery from in vivo selected hematopoietic stem cells following nonmyeloablative conditioning in hemophilia B miceTherapeutic application of RNAi: is mRNA targeting finally ready for prime time?Hematopoietic stem cell engineering at a crossroadsGene therapy studies in a canine model of X-linked severe combined immunodeficiencyCorrection of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapyGene therapy of MPL deficiency: challenging balance between leukemia and pancytopenia.Correction of murine Bernard-Soulier syndrome by lentivirus-mediated gene therapy.Engineering humanized mice for improved hematopoietic reconstitution.Gene therapy: design and prospects for craniofacial regeneration.Quantification of lentiviral vector copy numbers in individual hematopoietic colony-forming cells shows vector dose-dependent effects on the frequency and level of transduction.Clinical-scale lentiviral vector transduction of PBL for TCR gene therapy and potential for expression in less-differentiated cells.Engineering lymphocyte subsets: tools, trials and tribulationsModern treatment of thalassaemia intermedia.Harnessing endogenous miR-181a to segregate transgenic antigen receptor expression in developing versus post-thymic T cells in murine hematopoietic chimeras.Noninvasive imaging of cell-mediated therapy for treatment of cancer.Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognitionEffect of ex vivo culture of CD34+ bone marrow cells on immune reconstitution of XSCID dogs following allogeneic bone marrow transplantation.A simple and effective method to generate lentiviral vectors for ex vivo gene delivery to mature human peripheral blood lymphocytesReprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome.Targeted approaches for gene therapy and the emergence of engineered meganucleases.Supplying clotting factors from hematopoietic stem cell-derived erythroid and megakaryocytic lineage cells.Gene therapy for β-thalassaemia: the continuing challenge.Elimination of blood group antigens: hope and reality.The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectorsGenotoxicity of retroviral hematopoietic stem cell gene therapy.Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity.Genetic strategies for the treatment of sickle cell anaemia.Cell and Gene Therapy for the Beta-Thalassemias: Advances and Prospects.Physiological regulation of transgene expression by a lentiviral vector containing the A2UCOE linked to a myeloid promoter.Improving miRNA Delivery by Optimizing miRNA Expression Cassettes in Diverse Virus Vectors.DNA/RNA-based formulations for treatment of breast cancer.Locus control region elements HS1 and HS4 enhance the therapeutic efficacy of globin gene transfer in beta-thalassemic mice.Screen and Verification for Transgene Integration Sites in Pigs.Safe harbours for the integration of new DNA in the human genome
P2860
Q21245112-5026C36C-778C-45E9-B152-A34623AEFFAEQ24654670-5F687DBE-020D-4EF9-94AD-E2DE2511D3EBQ24669624-724FFA8B-7048-4593-9C7E-DC72AE9EDB76Q27001570-0024A3F1-F710-4252-95D7-6046C9B67472Q27026069-3B85F038-1190-4E03-B1F0-4544566469AAQ33382766-97CCED98-9146-41CB-A10E-4019DBBD3475Q33386724-8B1A7DEC-C2BD-4B35-9CEF-327B0C3544A6Q33397933-6E5ECE10-B819-4B0D-B9C4-C29872C12ACBQ33844310-6BF4B701-EC36-4E04-8CEE-24A286717840Q34007347-6EF95228-E48C-4839-9B06-3E0A54230208Q35087824-94286F39-3A81-41B5-B925-65F5A4821448Q36102927-1CEFE1AB-D99C-4806-AA4F-2954507022FEQ36140986-D0DE4440-FC02-46C9-868E-1E2C20F70B83Q36848269-C81D2095-A216-4827-86EA-FC0BD024D012Q37036104-BDF36352-E55E-45E8-86D1-EC446E98CC2BQ37181560-FFC21D51-56EB-4F48-8C3F-0617A6DD67A7Q37197942-08DAEFB3-F173-49B0-BF42-30454384D161Q37199007-28219B21-D8D7-429D-AFB3-9061802C9F3AQ37358371-9310399A-BDF7-48E7-8709-12BDD6A8552DQ37446490-77D56BA3-EDF0-41DB-A811-2BC76E1F7183Q37581606-0C9E7617-91F4-4677-909A-CF9A70E8EFCAQ37618532-465E1C33-A8AB-45B8-B6B6-812B14FF21B2Q37795125-24D120C2-3E1F-4CA4-85DA-4F1A56CD2C37Q37826438-053AEAC8-9EA2-4973-BA82-697C464A1FA1Q37830029-649B5E6C-AD0F-4FD4-B4EC-2F9E230E238AQ37849774-95DED82D-C149-4F3E-8527-624482C4A2D4Q37857291-F394EF08-2C4A-4ED0-8560-8F24B263D08CQ37894826-22D66863-F0A9-4BB7-AE2A-0DAA660FBA2BQ38791734-0D3331AF-EF53-47F5-82D6-2236BD36F375Q39445622-F817A13C-EAB8-4FF5-A329-6FEFF4DB6C20Q40121209-4C24BF62-C133-4303-A2F7-19A4B4B23230Q40252910-2435C7C5-0140-4054-9DA3-A01FA70744ABQ41954465-B7F03F2F-95D8-43A4-9750-8A8359206E29Q55008006-F30023F3-F312-42A8-9EE0-F155026E3B0DQ57008552-7C2A39CF-F3F3-4C98-8471-162425DD3CA3
P2860
The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The genetic engineering of hem ...... of lineage-restricted vectors.
@ast
The genetic engineering of hem ...... of lineage-restricted vectors.
@en
type
label
The genetic engineering of hem ...... of lineage-restricted vectors.
@ast
The genetic engineering of hem ...... of lineage-restricted vectors.
@en
prefLabel
The genetic engineering of hem ...... of lineage-restricted vectors.
@ast
The genetic engineering of hem ...... of lineage-restricted vectors.
@en
P356
P1433
P1476
The genetic engineering of hem ...... of lineage-restricted vectors.
@en
P2093
Alex H Chang
Michel Sadelain
P304
P356
10.1038/SJ.MT.6300060
P577
2007-01-16T00:00:00Z